Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Immunomedics Inc.
DescriptionTrivalent, bispecific antibody generated via the dock and lock (DNL) method that targets the carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5) (CD66e)
Molecular Target Carcinoembryonic antigen (CEA)-related cell adhesion molecule 5 (CEACAM5) (CD66e)
Mechanism of ActionDiagnostic; Imaging agent; Bispecific antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationColorectal cancer
Indication DetailsTreat advanced colorectal cancer; Treat colorectal cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today